Medtronic is ramping up the rollout of Symplicity Spyral after receiving the CMS NCD in October. CEO Geoff Martha, on an earnings call this week, said the company is putting resources into market development efforts such as a direct-to-consumer website that has seen a spike in visits.

The investment includes hiring for roles that support the development of referral pathways from general practitioners and hypertension specialists to the hospital, and for positions in health economics and coding and billing.

“We’d also like to build the brand of Symplicity and make it synonymous with hypertension management,” Martha said.